Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria . Approval based on phase 3 studies demonstrating Dupixent signifi ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

A Q&A between Shawn Kwatra, M.D., professor and chair of dermatology at the University of Maryland School of Medicine, and Managed Healthcare Executive about new discoveries in chronic itch, how ...

Dupixent (dupilumab ... further into areas like chronic obstructive pulmonary disease (COPD), bullous pemphigoid, prurigo nodularis, chronic hives, and allergies. In trials, tralokinumab ...

Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous ...

Sanofi and Regeneron's fast-growing immunology drug Dupixent is on course for a third indication in Europe after being recommended for approval as a treatment for people with nasal polyps.

Dupixent topped Rx and over-the-counter (OTC) pharma brands for ad impressions during Q1 2025, according to data released by iSpot.tv on Monday afternoon. The Regeneron and Sanofi brand for asthma and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In 9 out of 10 cases, children are under the age of 2 years. Bullous impetigo begins with small blisters that often affect the trunk of the body. They can also appear on the mouth. The blisters ...